Lipoprotein(a), usually written as Lp(a), is a cholesterol-carrying particle that can raise the risk of heart attack, stroke, peripheral artery disease, and calcific aortic valve stenosis even when standard cholesterol numbers look acceptable. The Lp(a) blood test measures how much of this inherited particle is in your bloodstream. Unlike LDL cholesterol or triglycerides, Lp(a) is controlled mostly by genetics, so diet, exercise, and weight loss usually do not lower it very much.
A high result does not mean heart disease is certain, but it can change how aggressively other risk factors should be managed. Someone with high Lp(a) often benefits from tighter LDL cholesterol or ApoB control, careful blood pressure management, not smoking, and earlier family screening. The test is simple, usually does not require fasting, and often needs to be checked only once unless there is a specific reason to repeat it.
- Lp(a) measures an inherited LDL-like particle that carries apolipoprotein(a), a protein linked with artery plaque and aortic valve calcification.
- High Lp(a) is commonly defined as 50 mg/dL or higher, or 125 nmol/L or higher, but risk rises gradually rather than at one single cutoff.
- A low or normal Lp(a) result is usually below 30 mg/dL or below 75 nmol/L, depending on the lab and unit used.
- Fasting is usually not required because Lp(a) changes very little after meals.
- High Lp(a) often runs in families, so first-degree relatives may need testing if one person has a high result.
- There is no widely used medication approved only for routine Lp(a) lowering, but LDL-lowering treatment, selected PCSK9 inhibitors, and, in severe cases, lipoprotein apheresis may reduce overall risk.
Table of Contents
- What the Lp(a) Test Measures
- Lp(a) Normal Range and High Levels
- Why High Lp(a) Raises Heart and Valve Risk
- Genetics, Inheritance, and Family Testing
- Who Should Get an Lp(a) Test
- How to Prepare and Understand Your Result
- What to Do if Lp(a) Is High
- Common Mistakes and Next Steps
What the Lp(a) Test Measures
The Lp(a) test measures the amount of lipoprotein(a) particles in your blood. Lp(a), pronounced “L-P-little-a,” looks similar to an LDL particle, but it has an extra protein attached to it called apolipoprotein(a), or apo(a). That extra protein changes the way the particle behaves in the arteries.
LDL cholesterol mainly tells you how much cholesterol is carried inside LDL particles. Lp(a) is different because it identifies a specific inherited particle that can carry cholesterol, oxidized phospholipids, and apo(a). These features may make it more likely to contribute to plaque buildup, artery inflammation, and calcification of the aortic valve.
A standard lipid panel does not usually include Lp(a). Many people with high Lp(a) have never had it measured because their total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides may not look unusual enough to trigger extra testing. Lp(a) may be included in an advanced lipid panel, but it can also be ordered as a separate blood test.
Lp(a) is not the same as ApoB, LDL particle number, small dense LDL, or non-HDL cholesterol. Those markers describe the broader number or type of atherogenic particles, while Lp(a) identifies one genetically influenced particle with its own risk pattern. Still, these markers often belong in the same conversation because a person with high Lp(a) may need especially strong control of other plaque-forming lipoproteins, including ApoB.
Most of the Lp(a) level comes from the liver and is set by inherited LPA gene variation. Lifestyle habits strongly affect blood pressure, insulin resistance, triglycerides, body weight, smoking-related risk, and many other cardiovascular factors, but they usually do not move Lp(a) by much. This is why someone can be lean, active, and eating well yet still have a high Lp(a) result.
The test is useful because it can explain hidden risk. For example, a person may have “normal” LDL cholesterol but a strong family history of early heart attacks. Another person may have had a heart attack despite reasonable cholesterol numbers. Lp(a) is one of the markers that can help reveal why standard testing did not tell the full story.
Lp(a) Normal Range and High Levels
A normal or desirable Lp(a) result is often considered below 30 mg/dL or below 75 nmol/L. A high result is commonly considered 50 mg/dL or higher, or 125 nmol/L or higher. Values between these ranges are often treated as borderline or intermediate, especially when other risk factors are present.
Lp(a) reporting can be confusing because labs use two different units:
- mg/dL estimates the mass of Lp(a).
- nmol/L estimates the particle concentration.
The two units cannot be converted with one exact formula. Lp(a) particles vary in size because apo(a) varies from person to person. A simple conversion can misclassify some people, especially near treatment thresholds. The safest approach is to interpret your result in the unit your lab used and compare it with that lab’s reference range.
| Category | Approximate mg/dL range | Approximate nmol/L range | Usual meaning |
|---|---|---|---|
| Low or desirable | Below 30 mg/dL | Below 75 nmol/L | Usually not a major inherited Lp(a)-related risk factor |
| Borderline or intermediate | 30–49 mg/dL | 75–124 nmol/L | May add risk, especially with other cardiovascular risk factors |
| High | 50 mg/dL or higher | 125 nmol/L or higher | Often treated as a risk-enhancing result |
| Very high | About 180 mg/dL or higher | About 430 nmol/L or higher | Can signal a large inherited lifetime risk burden |
These cutoffs are not disease diagnoses by themselves. Risk rises across a continuum, which means a person at 49 mg/dL is not suddenly “safe” while a person at 50 mg/dL is suddenly “dangerous.” The number becomes more meaningful when combined with age, blood pressure, LDL cholesterol, ApoB, diabetes status, smoking history, kidney disease, family history, and any known plaque or vascular disease.
Low Lp(a) usually does not need treatment. Very low Lp(a) has been linked in some studies with a slightly higher chance of type 2 diabetes, but this is not treated like a deficiency, and clinicians do not usually try to raise Lp(a). For most people, the concern is elevated Lp(a), not low Lp(a).
A high result should be checked carefully for the unit used. A value of 80 mg/dL and a value of 80 nmol/L do not mean the same thing. The first is usually high; the second may be borderline or moderate depending on the lab. This unit issue is one of the most common reasons people misunderstand their result.
Why High Lp(a) Raises Heart and Valve Risk
High Lp(a) raises cardiovascular risk because it can contribute to plaque formation, inflammation inside artery walls, and calcification. It is linked most strongly with atherosclerotic cardiovascular disease, which includes coronary artery disease, heart attack, ischemic stroke, and peripheral artery disease. It is also linked with calcific aortic valve stenosis, a condition in which the aortic valve becomes stiff and narrowed.
Lp(a) can be risky even when LDL cholesterol is not extremely high. That is because Lp(a) is not only a cholesterol carrier. It also carries oxidized phospholipids, which may promote inflammation in plaques. Apo(a) also resembles plasminogen, a protein involved in clot breakdown, although the real-world clotting effects of Lp(a) are complex and should not be reduced to a simple “thick blood” explanation.
The risk from Lp(a) is cumulative. A person with genetically high Lp(a) is exposed to that level for decades. This lifetime exposure may help explain why some families have early heart attacks even when lifestyle habits seem reasonable. It may also help explain why some people continue to have cardiovascular events after LDL cholesterol has been improved.
High Lp(a) does not act alone. It becomes more concerning when combined with other risk drivers, such as:
- High LDL cholesterol or high ApoB
- High blood pressure
- Smoking or nicotine exposure
- Diabetes, prediabetes, or insulin resistance
- Chronic kidney disease
- Inflammatory conditions
- Strong family history of premature heart disease
- Existing plaque seen on imaging or prior cardiovascular events
The aortic valve connection is important. Lp(a) is associated with calcific aortic valve stenosis, especially when levels are high over many years. This does not mean every person with high Lp(a) needs an echocardiogram right away. It does mean that symptoms such as exertional chest pressure, fainting, unusual shortness of breath, or a new heart murmur should be evaluated promptly.
Lp(a) is also a useful “risk enhancer.” That term means the result can shift a person into a more intensive prevention plan when standard risk calculators underestimate risk. For example, a middle-aged person with borderline LDL cholesterol and a strong family history may receive different advice if Lp(a) is very high.
Genetics, Inheritance, and Family Testing
High Lp(a) is mainly inherited. The LPA gene influences how much apo(a) your liver makes and how large that apo(a) protein is. Smaller apo(a) forms are often linked with higher Lp(a) levels, although the full genetics are more complex than one simple mutation.
Because Lp(a) is genetic, levels often cluster in families. If one person has a high result, parents, siblings, and children may also have high levels. This is called cascade testing when relatives are checked after an affected family member is identified.
Family testing is especially useful when there is premature cardiovascular disease. Premature usually means a heart attack, stroke, coronary stent, bypass surgery, or significant artery disease before age 55 in men or before age 65 in women. A family history like that should raise suspicion for inherited risk factors, including high Lp(a), familial hypercholesterolemia, or both.
High Lp(a) can overlap with familial hypercholesterolemia, a genetic condition that causes very high LDL cholesterol from birth. When both are present, lifetime risk may be much higher than either condition alone. This is one reason clinicians may order Lp(a) in people with severe LDL elevation, early heart disease, or a family pattern of high cholesterol.
Lp(a) levels differ across ancestry groups. People of African ancestry often have higher average Lp(a) levels than people of European or East Asian ancestry, but risk interpretation still depends on the individual result and overall risk profile. The same number can carry different context depending on age, blood pressure, LDL cholesterol, diabetes, smoking, and whether cardiovascular disease is already present.
Children do not need universal Lp(a) testing in every situation, but testing may be considered when there is a known family history of very high Lp(a), familial hypercholesterolemia, or premature cardiovascular disease. A high result in a young person should not lead to fear-based treatment. It should lead to lifelong risk awareness, healthy habits, and careful management of modifiable risk factors.
Lp(a) usually remains fairly stable after childhood. Hormonal changes, kidney disease, severe inflammation, pregnancy, liver disease, and some medications may influence levels, but genetics remains the main driver. Because of this stability, many adults need the test only once.
Who Should Get an Lp(a) Test
Many lipid experts now support measuring Lp(a) at least once in adulthood because the result is mostly inherited and may uncover risk that a standard cholesterol panel misses. Testing is especially important when personal or family history suggests more risk than routine numbers show.
An Lp(a) test is particularly reasonable for people with:
- Heart attack, stroke, peripheral artery disease, or coronary artery disease at a young age
- A parent, sibling, or child with premature heart disease
- Known familial hypercholesterolemia or very high LDL cholesterol
- Recurrent cardiovascular events despite LDL-lowering treatment
- Calcific aortic valve stenosis, especially at a younger age
- Borderline or intermediate cardiovascular risk where the result could affect treatment decisions
- A first-degree relative with known high Lp(a)
Lp(a) may also be helpful when LDL cholesterol seems acceptable but other signs point toward hidden risk. Examples include a high coronary artery calcium score, plaque found on a coronary CT angiogram, or unexplained vascular disease. In these cases, Lp(a) can help explain why plaque developed and how intensive prevention should be.
The test should not replace standard risk assessment. A person with high Lp(a) still needs a regular lipid panel, blood pressure measurement, diabetes screening, smoking assessment, kidney function testing, and a careful family history. In many people, non-HDL cholesterol and ApoB help show how many plaque-forming particles are present in addition to Lp(a).
Testing is also useful before assuming that “normal cholesterol” means low risk. Standard LDL cholesterol calculations can include cholesterol carried inside Lp(a), but they do not identify Lp(a) directly. Two people with the same LDL cholesterol may have very different inherited risk if one has high Lp(a) and the other does not.
A high Lp(a) result can also guide conversations about earlier prevention. For example, a clinician may be more likely to recommend earlier LDL-lowering medication, tighter LDL targets, coronary artery calcium scoring, or referral to a lipid specialist when Lp(a) is very high and the family history is concerning.
How to Prepare and Understand Your Result
The Lp(a) test is a routine blood draw. Fasting is usually not needed because Lp(a) does not rise and fall after meals the way triglycerides can. If the same blood draw includes triglycerides, glucose, insulin, or other markers that require fasting, your clinician may still ask you to fast for the whole panel.
Before the test, tell your clinician about major recent illness, pregnancy, kidney disease, thyroid disease, liver disease, and lipid-lowering medications. These factors do not erase the genetic meaning of Lp(a), but they may affect interpretation or the decision to repeat testing.
When you receive your result, check four details:
- The number
- The unit, either mg/dL or nmol/L
- The lab’s reference range
- Your overall cardiovascular context
A result of 140 nmol/L is commonly considered high. A result of 140 mg/dL is much higher. This is why the unit should be written down whenever you discuss the result.
Repeat testing is not always necessary. Because Lp(a) is genetically determined, one reliable adult measurement is often enough. A repeat test may be useful if the result was unexpected, the unit seems unclear, the lab used an older assay, the sample was taken during a major illness, or a clinician is considering a specialized therapy.
The best Lp(a) assays are designed to reduce the effect of apo(a) particle size on the result. This matters because apo(a) size varies from person to person. If your result is being used for an important treatment decision, your clinician may prefer a lab method that reports in nmol/L and is less affected by apo(a) isoform size.
Lp(a) should be interpreted alongside other results. A useful follow-up blood work discussion may include LDL cholesterol, ApoB, non-HDL cholesterol, triglycerides, hemoglobin A1c, kidney function, and sometimes hs-CRP if inflammation-related cardiovascular risk is being assessed. If insulin resistance is part of the concern, fasting glucose, A1c, and sometimes fasting insulin may help complete the picture.
A high Lp(a) result is not an emergency by itself. Chest pain, stroke symptoms, fainting, severe shortness of breath, or sudden weakness are emergencies regardless of Lp(a). The test helps with prevention and risk planning; it is not used to diagnose an active heart attack or stroke.
What to Do if Lp(a) Is High
High Lp(a) should lead to stronger cardiovascular prevention, not panic. Since Lp(a) itself is hard to lower with routine lifestyle changes, the main strategy is to reduce every other risk factor that can be changed. The aim is to lower the total burden on the arteries.
Lower LDL cholesterol and ApoB more aggressively
LDL cholesterol and ApoB are the most actionable targets when Lp(a) is high. Lowering LDL cholesterol does not remove the inherited Lp(a) particle, but it reduces the total number of plaque-forming particles and lowers event risk. In many people, this is the most practical way to offset part of the added inherited risk.
Statins usually do not lower Lp(a), and they may slightly increase it in some people. Even so, statins reduce cardiovascular events by lowering LDL cholesterol and ApoB, so a high Lp(a) result is not a reason to avoid statins when they are otherwise indicated.
Ezetimibe can further lower LDL cholesterol. PCSK9 inhibitors can lower LDL cholesterol substantially and often reduce Lp(a) by about 20% to 30%, though their main approved role is LDL cholesterol lowering and cardiovascular risk reduction. Inclisiran lowers LDL cholesterol through PCSK9-related RNA interference and may have modest Lp(a) effects, but it is not an Lp(a)-specific treatment.
Niacin can lower Lp(a), but it is not commonly recommended just for Lp(a) because outcome benefits have not been convincing in modern trials and side effects can be significant. Supplements marketed for Lp(a) should be treated with caution unless a clinician has reviewed the evidence and safety.
Use lifestyle to lower total risk
Lifestyle usually does not lower Lp(a) much, but it still matters greatly. A person with high Lp(a) has more reason to protect the arteries from other stressors.
Useful steps include:
- Do not smoke or vape nicotine.
- Keep blood pressure in a healthy range.
- Follow a heart-protective eating pattern rich in minimally processed foods, fiber, legumes, vegetables, fruit, nuts, fish, and unsaturated fats.
- Replace excess saturated fat with unsaturated fats when LDL cholesterol is high.
- Exercise regularly, combining aerobic activity with strength training.
- Treat sleep apnea if present.
- Manage diabetes, prediabetes, and insulin resistance early.
- Maintain a waist size and body weight that support metabolic health.
These steps may not make the Lp(a) number fall, but they can reduce the chance that high Lp(a) turns into plaque progression or an event.
Consider imaging or specialist care when risk is unclear
Some people with high Lp(a) benefit from further risk assessment, especially if the decision about medication is uncertain. Coronary artery calcium scoring may help show whether calcified plaque is already present. Other imaging may be used when symptoms or clinical history suggest disease.
A lipid specialist or preventive cardiologist may be helpful when Lp(a) is very high, there is premature heart disease, LDL cholesterol remains above target, or cardiovascular events occur despite treatment. Specialist care can also help with insurance approval for advanced lipid therapy or evaluation for lipoprotein apheresis.
Know where apheresis and new therapies fit
Lipoprotein apheresis is a procedure that filters ApoB-containing particles, including LDL and Lp(a), from the blood. It is usually reserved for selected high-risk patients, often those with progressive cardiovascular disease and severe inherited lipid problems. It is not a simple first-line treatment and requires repeated sessions.
Several Lp(a)-targeted medications are in advanced clinical trials. These include RNA-based therapies designed to reduce apo(a) production in the liver. Some have lowered Lp(a) dramatically in trials, but the major clinical question is whether lowering Lp(a) reduces heart attacks, strokes, valve disease, and cardiovascular death. Until outcome data and approvals are clear, high Lp(a) management still centers on aggressive overall risk reduction.
Common Mistakes and Next Steps
A common mistake is assuming that high Lp(a) means nothing can be done. The number itself may be difficult to change, but the risk attached to it can often be reduced. LDL cholesterol, ApoB, blood pressure, smoking, diabetes, weight, sleep, and inflammation are all modifiable parts of the same risk picture.
Another mistake is assuming that a healthy lifestyle rules out high Lp(a). Lp(a) is mostly genetic. A marathon runner, a vegetarian, or someone with a normal body weight can still have a high result. Lifestyle reflects effort and health habits; Lp(a) reflects inherited biology.
Many people also confuse Lp(a) with LDL cholesterol. They are related but not interchangeable. LDL cholesterol can improve dramatically while Lp(a) stays high. That is why Lp(a) may remain a residual risk factor even after standard cholesterol treatment looks successful.
Do not use a rough online conversion between mg/dL and nmol/L to make treatment decisions. The relationship between the units depends on apo(a) particle size, so conversions are only estimates. The original lab unit is the one to use.
Do not chase unproven Lp(a)-lowering supplement plans at the expense of proven prevention. A supplement that changes a lab value slightly is not the same as a treatment that reduces heart attacks or strokes. Safety matters too, especially with high-dose niacin, hormone-related products, or combinations that affect the liver, blood sugar, or bleeding risk.
A practical follow-up plan after a high Lp(a) result may look like this:
- Confirm the unit and result category.
- Review family history for premature heart disease, stroke, valve disease, or very high cholesterol.
- Check LDL cholesterol, ApoB or non-HDL cholesterol, triglycerides, blood pressure, A1c, kidney function, and smoking status.
- Discuss whether LDL cholesterol or ApoB goals should be lower because of high Lp(a).
- Ask whether first-degree relatives should be tested.
- Consider referral to a lipid specialist if Lp(a) is very high, disease is premature, or events have occurred despite treatment.
- Revisit the plan periodically as new Lp(a)-targeted therapies and outcome data become available.
High Lp(a) is best handled as a lifelong risk marker. It gives you and your clinician a clearer view of inherited cardiovascular risk, but it does not predict a single unavoidable outcome. The most useful response is earlier, more precise prevention.
References
- A Focused Update to the 2019 NLA Scientific Statement on Use of Lipoprotein(a) in Clinical Practice 2024 (Scientific Statement)
- Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement 2022 (Consensus Statement)
- Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society 2023 (Review)
- Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease 2022 (RCT)
- Design and Rationale of Lp(a)HORIZON Trial: Assessing the Effect of Lipoprotein(a) Lowering With Pelacarsen on Major Cardiovascular Events in Patients With CVD and Elevated Lp(a) 2025 (Trial Design)
- The Off-Treatment Effects of Olpasiran on Lipoprotein(a) Lowering: OCEAN(a)-DOSE Extension Period Results 2024 (RCT Extension)
Disclaimer
Lp(a) results should be interpreted with a qualified healthcare professional who can review your full cardiovascular risk profile, family history, medications, and other test results. A high Lp(a) result is not an emergency by itself, but chest pain, stroke symptoms, fainting, or severe shortness of breath need urgent medical care. Do not start, stop, or change cholesterol-lowering treatment based only on an Lp(a) result without medical guidance.
